Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B trial): protocol for a mixed-methods process evaluation of a randomised controlled trial
Introduction
An association between deep sedation and adverse short-term outcomes has been demonstrated although this evidence has been inconsistent. The A2B (alpha-2 agonists for sedation in critical care) sedation trial is designed to determine whether the alpha-2 agonists clonidine and dexmedetomidine, compared with usual care, are clinically and cost-effective. The A2B intervention is a complex intervention conducted in 39 intensive care units (ICUs) in the UK. Multicentre organisational factors, variable cultures, perceptions and practices and the involvement of multiple members of the healthcare team add to the compl...
Source: BMJ Open - April 5, 2024 Category: General Medicine Authors: Aitken, L. M., Emerson, L. M., Kydonaki, K., Blackwood, B., Creagh-Brown, B., Lone, N. I., McKenzie, C. A., Reade, M. C., Weir, C. J., Wise, M. P., Walsh, T. S. Tags: Open access, Intensive care Source Type: research
Alpha Alert: Utilization of Transdermal Clonidine for Refractory Agitation
We report a case of agitated behaviors in setting of mixed Alzheimer/vascular-type dementia limiting hospital discharge to nursing facility that were ameliorated with transdermal clonidine. We suggest palliative clinicians routinely conceptualize the seemingly disparate alpha-2 agonists as a class for effective symptom palliation especially as new clinical evidence becomes available.PMID:38484176 | DOI:10.1080/15360288.2024.2327868 (Source: Journal of Pain and Palliative Care Pharmacotherapy)
Source: Journal of Pain and Palliative Care Pharmacotherapy - March 14, 2024 Category: Palliative Care Authors: Samantha Grable Gary Houchard Zach Rossfeld Source Type: research
